

Unveiling the nonlinear pharmacokinetics of topical Flurbiprofen gel: Implications for clinical practice.

Angela Uskew*

Department of Pharmacy, Cairo University, Cairo, Egypt

Received: 29 January, 2024, Manuscript No. AJPTI-24-130371; **Editor assigned:** 31 January, 2024, Pre QC No. AJPTI-24-130371 (PQ); **Reviewed:** 14 February, 2024, QC No. AJPTI-24-130371; **Revised:** 21 February, 2024, Manuscript No. AJPTI-24-130371 (R); **Published:** 28 February, 2024.

Accepted on 25th February, 2024

Description

Topical Flurbiprofen gel is a commonly prescribed Nonsteroidal Anti-Inflammatory Drug (NSAID) used for the management of musculoskeletal pain and inflammation. Despite its widespread use, the pharmacokinetics of topical Flurbiprofen gel exhibit nonlinear characteristics, posing challenges for dose optimization and therapeutic efficacy. This manuscript aims to elucidate the nonlinear pharmacokinetic behavior of topical Flurbiprofen gel, exploring factors influencing absorption, distribution, metabolism, and elimination. Understanding the nonlinear pharmacokinetics of topical Flurbiprofen gel is essential for optimizing therapeutic regimens and ensuring safe and effective pain management.

Flurbiprofen, a propionic acid derivative NSAID, exerts its anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis. Topical formulations of Flurbiprofen, including gels, creams, and patches, are preferred for localized pain relief due to their targeted delivery and reduced systemic side effects compared to oral administration. However, the pharmacokinetics of topical Flurbiprofen exhibit nonlinear behavior characterized by dose-dependent absorption kinetics and saturable metabolism pathways, necessitating careful consideration for therapeutic dosing.

The nonlinear pharmacokinetics of topical Flurbiprofen gel result from complex interactions between drug formulation, skin permeation, and systemic absorption processes. At low doses, the rate of Flurbiprofen absorption from the gel follows first-order kinetics, primarily driven by passive diffusion through the stratum corneum into the underlying tissues. However, as the dose increases, the absorption rate saturates due to limited skin permeation capacity and the formation of drug depots within the skin layers. Several factors influence the nonlinear pharmacokinetics of topical Flurbiprofen gel, including formulation characteristics (e.g., drug concentration, vehicle composition), application site, skin integrity, and concurrent use of occlusive dressings. Higher drug concentrations in the gel can lead to greater drug reservoir formation within the skin, resulting in prolonged absorption and systemic exposure. Additionally, variations in skin thickness, hydration, and blood flow at different application sites can affect drug permeation rates and systemic bioavailability.

Following systemic absorption, Flurbiprofen undergoes extensive hepatic metabolism *via* cytochrome P450 enzymes, primarily CYP2C9, to form inactive metabolites that are eliminated *via* renal excretion. However, the metabolic capacity of the liver can become saturated at higher doses or with repeated dosing, leading to nonlinear changes in systemic clearance and elimination half-life. Furthermore, accumulation of Flurbiprofen metabolites may occur with prolonged use, potentially contributing to adverse effects or drug interactions. Understanding the nonlinear pharmacokinetics of topical Flurbiprofen gel has important clinical implications for pain management. Dose titration based on individual patient response and consideration of maximum recommended daily doses are essential to avoid excessive systemic exposure and minimize the risk of adverse effects, such as gastrointestinal irritation or renal toxicity. Additionally, patient factors such as age, renal function, and concomitant medications should be taken into account when prescribing topical Flurbiprofen gel to optimize therapeutic outcomes while ensuring safety.

The nonlinear pharmacokinetics of topical Flurbiprofen gel pose challenges for dose optimization and therapeutic efficacy, necessitating careful consideration of factors influencing absorption, distribution, metabolism, and elimination. Understanding the complex interactions between drug formulation, skin permeation, and systemic absorption processes is essential for optimizing therapeutic regimens and ensuring safe and effective pain management. Further research is warranted to elucidate the mechanisms underlying nonlinear pharmacokinetics and develop strategies for personalized dosing approaches.

*Correspondence to:

Angela Uskew

Department of Pharmacy,

Cairo University,

Cairo, Egypt

E-mail: Uskewangela98@gmail.com

Citation: Uskew A. Unveiling the nonlinear pharmacokinetics of topical Flurbiprofen gel: Implications for clinical practice. *AJPTI* 2024;12 (46):1